These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 9358934)

  • 1. Topoisomerase I inhibitors: review and update.
    Rothenberg ML
    Ann Oncol; 1997 Sep; 8(9):837-55. PubMed ID: 9358934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topoisomerase I inhibitors in the treatment of colorectal cancer.
    Rothenberg ML; Blanke CD
    Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of topoisomerase I-targeting agents.
    Arbuck SG; Takimoto CH
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f.
    Nomoto T; Nishio K; Ishida T; Mori M; Saijo N
    Jpn J Cancer Res; 1998 Nov; 89(11):1179-86. PubMed ID: 9914787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
    Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
    Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of camptothecin analogs in childhood cancers.
    Bomgaars L; Berg SL; Blaney SM
    Oncologist; 2001; 6(6):506-16. PubMed ID: 11743213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan].
    Lavergne O; Bigg DC
    Bull Cancer; 1998 Dec; Spec No():51-8. PubMed ID: 9932086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity of the topoisomerase I inhibitors.
    Seiter K
    Expert Opin Drug Saf; 2005 Jan; 4(1):45-53. PubMed ID: 15709897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation.
    Lamond JP; Mehta MP; Boothman DA
    J Neurooncol; 1996 Oct; 30(1):1-6. PubMed ID: 8864997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues.
    Arun B; Frenkel EP
    Expert Opin Pharmacother; 2001 Mar; 2(3):491-505. PubMed ID: 11336601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical applications of the camptothecins.
    Takimoto CH; Wright J; Arbuck SG
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):107-19. PubMed ID: 9748525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical use of topoisomerase I inhibitors in anticancer treatment.
    Rodriguez-Galindo C; Radomski K; Stewart CF; Furman W; Santana VM; Houghton PJ
    Med Pediatr Oncol; 2000 Oct; 35(4):385-402. PubMed ID: 11025469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.
    Herben VM; Ten Bokkel Huinink WW; Schellens JH; Beijnen JH
    Pharm World Sci; 1998 Aug; 20(4):161-72. PubMed ID: 9762728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Camptothecin analogues in the treatment of non-small cell lung cancer.
    Ardizzoni A
    Lung Cancer; 1995 Apr; 12 Suppl 1():S177-85. PubMed ID: 7551927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Camptothecins: a review of their chemotherapeutic potential.
    Ulukan H; Swaan PW
    Drugs; 2002; 62(14):2039-57. PubMed ID: 12269849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
    Gerrits CJ; de Jonge MJ; Schellens JH; Stoter G; Verweij J
    Br J Cancer; 1997; 76(7):952-62. PubMed ID: 9328159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current status of camptothecin analogues as antitumor agents.
    Slichenmyer WJ; Rowinsky EK; Donehower RC; Kaufmann SH
    J Natl Cancer Inst; 1993 Feb; 85(4):271-91. PubMed ID: 8381186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
    Burris HA; Fields SM
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of camptothecin analogs in the treatment of cancer: a review.
    Kehrer DF; Soepenberg O; Loos WJ; Verweij J; Sparreboom A
    Anticancer Drugs; 2001 Feb; 12(2):89-105. PubMed ID: 11261892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
    Philippart P; Harper L; Chaboteaux C; Decaestecker C; Bronckart Y; Gordover L; Lesueur-Ginot L; Malonne H; Lavergne O; Bigg DC; da Costa PM; Kiss R
    Clin Cancer Res; 2000 Apr; 6(4):1557-62. PubMed ID: 10778989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.